Shrinking appetites: Will GLP-1 adoption in high-income countries accelerate Big Food’s push into low- and middle-income countries?
Brice Even, Abdul-Rahim Abdulai, Ramya Ambikapathi, Christophe Béné, Gina Kennedy, Mark Lundy · 2026
Read Shrinking appetites: Will GLP-1 adoption in high-income countries accelerate Big Food’s push into low- and middle-income countries? by Brice Even, Abdul-Rahim Abdulai, Ramya Ambikapathi, Christophe Béné, Gina Kennedy, Mark Lundy (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13430823.txt.
Description
Brice Even and colleagues argue that weight-loss drugs may push big food firms toward poorer countries. GLP-1 medicines such as Ozempic, Wegovy, and Zepbound are spreading fast in rich countries, with clear effects on shopping and eating.
Early United States household data show grocery spending falling about 5 percent within six months of a household member starting a GLP-1 drug. Falls ran bigger for richer households, and bigger still for snacks and energy-dense foods. Firms already sell smaller packs and GLP-1-friendly brands. The paper warns that if rich-world demand for ultra-processed food softens, firms may hedge by marketing harder where regulation is weaker.
Catalog record
| CREATOR | Brice Even, Abdul-Rahim Abdulai, Ramya Ambikapathi, Christophe Béné, Gina Kennedy, Mark Lundy |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |